PTC Therapeutics, Inc. Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized
PTC Therapeutics, Inc. (PTCT) reported Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized of $2.43 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-10-30.
Discontinued › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized · last filed 2019-10-30
- PTC Therapeutics, Inc. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for the quarter ending 2019-03-31 was $0.00.
- PTC Therapeutics, Inc. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for the quarter ending 2018-03-31 was $0.00.
- PTC Therapeutics, Inc. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for fiscal 2018 was $1.43M.
| Period end | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 3 month | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 6 month | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 9 month | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2019-09-30 | $2.43M 10-Q · filed 2019-10-30 | |||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-06 | |||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-02 | |||
| 2018-12-31 | $1.43M 10-K · filed 2019-03-01 | |||
| 2018-09-30 | $0.00 10-Q · filed 2019-10-30 | |||
| 2018-06-30 | $0.00 10-Q · filed 2019-08-06 | |||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |